Lee Ann Woodley, PA
Physician Assistant · Nash, NCNPI 1851833859
Payments from drug & device makers
Across 324 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$890
- AbbVie$575
- Lilly USA, LLC$426
- Amgen$378
- GSK$329
- AstraZeneca$312
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $890 |
| AbbVie | 32 | $575 |
| Lilly USA, LLC | 26 | $426 |
| Amgen | 27 | $378 |
| GSK | 20 | $329 |
| AstraZeneca(2 entities) | 20 | $312 |
| Bayer | 16 | $265 |
| Boehringer Ingelheim | 15 | $249 |
| Pfizer | 15 | $237 |
| Merck | 12 | $167 |
| Exact Sciences | 9 | $165 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $116 |
| Grifols USA, LLC | 5 | $113 |
| Abbott | 6 | $110 |
| Idorsia Pharmaceuticals US Inc | 6 | $109 |
| Amarin Pharma, Inc. | 5 | $83 |
| Corium, LLC | 3 | $68 |
| Hikma Pharmaceuticals USA | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Lundbeck LLC | 2 | $41 |
| Eisai Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Lifescan, Inc. | 1 | $22 |
| Boston Scientific | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Organon | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Cequr Corporation | 1 | $11 |
How this compares
$5,171 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 134 | $164,063 |
| OzempicSemaglutide | 105 | $145,952 |
| RybelsusSemaglutide | 36 | $52,786 |
| FarxigaDapagliflozin Propanediol | 44 | $48,454 |
| TrulicityDulaglutide | 30 | $47,858 |
| KerendiaFinerenone | 39 | $43,606 |
| EliquisApixaban | 45 | $38,520 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $33,304 |
| MounjaroTirzepatide | 21 | $31,445 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $16,790 |
| JanuviaSitagliptin Phosphate | 12 | $14,796 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,488 |
| Repatha SyringeEvolocumab | 11 | $5,974 |
| Atorvastatin Calcium | 458 | $4,053 |
| Losartan Potassium | 272 | $2,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $890 | $198,738141 claims |
| Boehringer IngelheimJardiance | $249 | $164,063134 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $312 | $81,75888 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $426 | $79,30351 claims |
| BayerKerendia | $265 | $43,60639 claims |
| PfizerEliquis | $237 | $38,52045 claims |
| MerckJanuvia | $167 | $14,79612 claims |
| GSKTrelegy Ellipta | $329 | $13,48817 claims |
| AbbVieSynthroid | $575 | $1,55719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Nash
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.